Biotech Ardelyx Beats Shareholder Suit Over Kidney Drug
Biotechnology company Ardelyx Inc. has for now beaten a shareholder class action alleging the company and its top brass made false and misleading statements about regulatory approval of Ardelyx's drug for...To view the full article, register now.
Already a subscriber? Click here to view full article